|
MechanismIL-23 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Effimune SA
0 Patents (Medical) associated with Effimune SA
100 Deals associated with Effimune SA
100 Translational Medicine associated with Effimune SA